Xaira Therapeutics

Company profile

About Xaira Therapeutics

Xaira Therapeutics is fundamentally transforming how medicines are discovered and developed by operating at the intersection of AI and drug development. The company has built a full-stack, AI-powered therapeutics engine called X-Suite that bridges digital and physical worlds. Their platform includes X-Cell for decoding disease biology using the largest single-cell genomic perturbation dataset ever generated, X-Design for computationally designing therapeutic molecules based on Nobel Prize-winning foundations, X-Patient for identifying responder populations, X-Scientist as an agentic AI research platform, and X-Automate for high-throughput lab automation. Unlike traditional biopharma approaches that rely on statistical correlations, Xaira directly measures biological system responses to perturbations at massive scale to learn actual causal disease mechanisms. The company unifies computational data analysis with physical lab experimentation under one roof, creating a virtuous cycle where every experimental result sharpens underlying AI models. Their emerging pipeline focuses on AI-derived biologic medicines, particularly antibody and protein therapeutics, addressing complex diseases. Xaira's mission is to develop 10x more medicines to help 10x more patients over the next 10 years, with particular focus on complex and historically underserved disease populations. The company's approach has already demonstrated success in rapidly creating drug-like antibody leads and drugging previously undruggable targets.

Company description · Xaira Therapeutics official website

Mission. We are fundamentally transforming how we discover and develop medicines—end to end. Purpose-built from inception to operate at the intersection of AI and drug development, we are united in our mission to decode disease, design therapies, and deliver cures.